TY - JOUR
T1 - Prevalence and features of asthma-COPD overlap in the United States 2007-2012
AU - Mendy, Angelico
AU - Forno, Erick
AU - Niyonsenga, Theophile
AU - Carnahan, Ryan
AU - Gasana, Janvier
PY - 2018/8
Y1 - 2018/8
N2 - Background
Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co‐exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma‐COPD overlap (ACO) in the US population.
Aims
To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO.
Methods
Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post‐bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7.
Results
Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age‐standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%–1.26%) and 1.05% (0.74%–1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non‐Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48–8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17–24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone.
Conclusion
Age‐adjusted prevalence of ACO in the United States was 1.05% in 2007–2012, representing 0.94 (95% CI: 0.62–1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.
AB - Background
Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co‐exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma‐COPD overlap (ACO) in the US population.
Aims
To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO.
Methods
Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post‐bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7.
Results
Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age‐standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%–1.26%) and 1.05% (0.74%–1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non‐Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48–8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17–24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone.
Conclusion
Age‐adjusted prevalence of ACO in the United States was 1.05% in 2007–2012, representing 0.94 (95% CI: 0.62–1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.
KW - ACO
KW - ACOS
KW - asthma
KW - asthma-COPD overlap
KW - COPD
KW - prevalence
U2 - 10.1111/crj.12917
DO - 10.1111/crj.12917
M3 - Article
VL - 12
SP - 2369
EP - 2377
JO - Clinical Respiratory Journal
JF - Clinical Respiratory Journal
SN - 1752-699X
IS - 8
ER -